By carefully calibrating N/OFQ administration, balanced coactivation of OPRL1 and mu opioid receptors is a strategy that warrants further exploration and refinement to manage cancer pain, thereby limiting opioid-associated side effects. The gene discussed is OPRM1; the disease is cancer.